What is the KLOW stack? KLOW is a community/commercial name used for a four-component peptide research blend commonly described as GHK-Cu, BPC-157, TB-500 and KPV. A commonly documented example contains 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV, for 80 mg total. However, KLOW is not a universally standardized pharmaceutical formulation.
KLOW is a name for a multi-component research blend, not the scientific name of one peptide. The commonly documented version contains GHK-Cu, BPC-157, TB-500 and KPV in one formulation.
The name should therefore be treated as a formulation label rather than a standardized chemical identity. Current references describe the commonly encountered 80 mg example as 50 mg GHK-Cu plus 10 mg each of BPC-157, TB-500 and KPV. :contentReference[oaicite:1]{index=1}
The commonly documented example contains four chemically distinct components. They remain separate molecules in the formulation rather than becoming a new single chemical compound. :contentReference[oaicite:2]{index=2}
GHK-Cu is a copper-associated tripeptide complex investigated in research involving extracellular-matrix biology, collagen-related processes and cellular signaling.
BPC-157 is a synthetic pentadecapeptide that has been studied primarily in preclinical research involving tissue injury, inflammation and gastrointestinal or musculoskeletal models.
TB-500 is commonly associated with the thymosin-beta-4 actin-binding fragment. Research involving full-length thymosin beta-4 should not automatically be treated as evidence for every TB-500 formulation.
KPV is the tripeptide Lys-Pro-Val, derived from the C-terminal region of alpha-melanocyte-stimulating hormone. Research has investigated inflammatory signaling and intestinal inflammation models.
The most useful distinction between the two names is composition: GLOW generally refers to the GHK-Cu + BPC-157 + TB-500 grouping, while KLOW adds KPV as a fourth component. However, formulation ratios can vary by source. :contentReference[oaicite:3]{index=3}
| Feature | GLOW | KLOW |
|---|---|---|
| GHK-Cu | Yes | Yes |
| BPC-157 | Yes | Yes |
| TB-500 | Yes | Yes |
| KPV | No | Yes |
| Universal formulation? | No | No |
| Combination clinical validation? | No | No |
The commonly documented KLOW example is an 80 mg total formulation containing 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV. This should be described as a commonly encountered formulation, rather than a universal pharmaceutical standard. :contentReference[oaicite:4]{index=4}
The name KLOW alone does not establish the contents of a particular vial. For concentration calculations, use the exact component masses stated on the product documentation.
If a product uses a different formulation, all concentration calculations on this page must be recalculated using those actual masses.
Research on the individual components must therefore remain separate from combination evidence. The presence of four independently researched peptides in the same vial does not demonstrate that the combination is effective, synergistic or safe.
This is particularly important when evaluating a multi-component formulation. Individual studies generally investigate one compound under specific experimental conditions. Those results cannot establish the pharmacology, stability, interactions or clinical outcomes of a different four-component formulation.
In a multi-component vial, each component retains its own mass, while all components share the same final liquid volume. Therefore, each component's concentration must be calculated independently.
Do not add all peptide masses together and then use that total as the concentration of every component. The total mass can describe the combined nominal peptide content, but each peptide has its own concentration.
| Component | Vial Mass | 1 mL | 2 mL | 3 mL | 5 mL |
|---|---|---|---|---|---|
| GHK-Cu | 50 mg | 50 mg/mL | 25 mg/mL | 16.67 mg/mL | 10 mg/mL |
| BPC-157 | 10 mg | 10 mg/mL | 5 mg/mL | 3.33 mg/mL | 2 mg/mL |
| TB-500 | 10 mg | 10 mg/mL | 5 mg/mL | 3.33 mg/mL | 2 mg/mL |
| KPV | 10 mg | 10 mg/mL | 5 mg/mL | 3.33 mg/mL | 2 mg/mL |
Changing the final liquid volume changes the concentration of every component proportionally. The mass of each component does not change simply because the final volume changes.
| Final Volume | GHK-Cu | BPC-157 | TB-500 | KPV |
|---|---|---|---|---|
| 1 mL | 50 mg/mL | 10 mg/mL | 10 mg/mL | 10 mg/mL |
| 2 mL | 25 mg/mL | 5 mg/mL | 5 mg/mL | 5 mg/mL |
| 3 mL | 16.67 mg/mL | 3.33 mg/mL | 3.33 mg/mL | 3.33 mg/mL |
| 5 mL | 10 mg/mL | 2 mg/mL | 2 mg/mL | 2 mg/mL |
The BacScience Universal BAC Water Calculator is primarily designed around single-compound concentration mathematics. For a multi-component formulation such as KLOW, each component should be calculated separately according to its own mass.
Open the BAC Water Calculator →| Evidence Layer | What it means | KLOW validation? |
|---|---|---|
| GHK-Cu | Independent biological and laboratory research. | No |
| BPC-157 | Predominantly preclinical research. | No |
| TB-500 / Tβ4 | Evidence must distinguish the TB-500 fragment from full-length thymosin beta-4. | No |
| KPV | Cellular and animal research. | No |
| Complete KLOW | No controlled human combination evidence identified. | No |
The principal limitation is that the KLOW name identifies a formulation concept rather than a universally standardized pharmaceutical product. Different suppliers or sources may use different ratios or packaging arrangements.
A second limitation is the lack of controlled clinical evidence for the complete four-component combination. Individual component research cannot establish combination efficacy, synergy, compatibility or safety.
A concentration calculation also does not establish peptide identity, purity, sterility, stability or suitability for administration. Those properties require appropriate analytical and pharmaceutical evidence.
Regulatory status depends on the jurisdiction, compound, formulation and intended use. The status of an individual peptide should not be assumed to establish regulatory approval of a multi-component KLOW formulation.